Stromal cell derived factor 1 plasmid to regenerate the anal sphincters

被引:1
|
作者
Sun, Li [1 ]
Billups, Alanna [1 ]
Rietsch, Anna [1 ]
Damaser, Margot S. [1 ,2 ,3 ]
Zutshi, Massarat [1 ,4 ]
机构
[1] Cleveland Clin, Dept Biomed Engn, Cleveland, OH USA
[2] Cleveland Clin, Glickman Urol & Kidney Inst, Cleveland, OH USA
[3] Vet Affairs Med Ctr, Adv Platform Technol Ctr, Louis Stokes Cleveland Dept, Cleveland, OH USA
[4] Cleveland Clin, Dept Colorectal Surg, 9500 Euclid Ave A30, Cleveland, OH 44195 USA
关键词
fecal incontinence; morphometry; muscle regeneration; swine; MESENCHYMAL STEM-CELLS; SKELETAL-MUSCLE; SUCCESSFUL IMPLANTATION; POLYCAPROLACTONE BEADS; AUTOLOGOUS MYOBLASTS; PROGENITOR CELLS; DOG-MODEL; THERAPY; INJURY; SDF-1;
D O I
10.1002/term.3283
中图分类号
Q813 [细胞工程];
学科分类号
摘要
The aim of this study was to evaluate regeneration of a chronic large anal sphincter defect in a pig model after treatment with a plasmid encoding Stromal Cell Derived Factor-1(SDF-1). Methods Under ethics approved protocol 19 age/weight matched Sinclair mini-pigs were subjected to excision of the posterior 50% of anal sphincter muscle and left to recover for 6 weeks. They were randomly allocated to receive either saline treatment (Saline 1 ml, n = 5), 1 injection of SDF-1 plasmid 2 mg/ml (1 SDF-1, n = 9) or 2 injections of SDF-1, 2 mg/ml each at 2 weeks intervals (2 SDF-1, n = 5). Euthanasia occurred 8 weeks after the last treatment. In vivo outcomes included anal resting pressures done under anesthesia pre-injury, pre-injection and before euthanasia (8 weeks after treatment). Anal ultrasound was done pre injury and pre-euthanasia. Tissues were saved for histology and analyzed quantitatively. Two way ANOVA followed by Holm-Sidak test and one way ANOVA followed by the Tukey test were used for data analysis, p < 0.05 was regarded as significant. Results Posterior anal pressures at the 3 time points were not significantly different in the saline group. In contrast, post-treatment pressures in the 1 SDF-1 group pressures were significantly higher than both pre-injury (p = 0.001) and pre-treatment time points (p = 0.003). At the post-treatment time point, both 1 SDF-1 (p = 0.01) and 2 SDF-1 (p = 0.01) groups had significantly higher mean pressures compared to the saline group. Histology showed distortion of normal anatomy with patchy regeneration in the control group while muscle was more organized in both treatment groups. Conclusions Eight weeks after a single or two doses of SDF-1injected into a chronic anal sphincter injury improved resting anal pressures and regenerated muscle in the entire defect. SDF-1 plasmid is effective in treating chronic defects of the anal sphincter in a large animal and could be clinically translated.
引用
收藏
页码:355 / 366
页数:12
相关论文
共 50 条
  • [21] Stromal cell-derived factor 1 expression in various skin tumours
    Chen, S-J.
    Nakahara, T.
    Kido, M.
    Takahara, M.
    Uchi, H.
    Takeuchi, S.
    Dugu, L.
    Tu, Y-T.
    Moroi, Y.
    Furue, M.
    BRITISH JOURNAL OF DERMATOLOGY, 2009, 160 (03) : 710 - 713
  • [22] Stromal derived factor-1 plasmid as a novel injection for treatment of stress urinary incontinence in a rat model
    Ahmad O. Khalifa
    Michael Kavran
    Amr Mahran
    Ilaha Isali
    Juliana Woda
    Chris A. Flask
    Marc S. Penn
    Adonis K. Hijaz
    International Urogynecology Journal, 2020, 31 : 107 - 115
  • [23] Stromal derived factor-1 plasmid as a novel injection for treatment of stress urinary incontinence in a rat model
    Khalifa, Ahmad O.
    Kavran, Michael
    Mahran, Amr
    Isali, Ilaha
    Woda, Juliana
    Flask, Chris A.
    Penn, Marc S.
    Hijaz, Adonis K.
    INTERNATIONAL UROGYNECOLOGY JOURNAL, 2020, 31 (01) : 107 - 115
  • [24] Stromal cell derived factor-1 mediates myeloid derived suppressor cell expansion during polymicrobial sepsis
    Delano, Matthew J.
    Winfield, Robert D.
    Scumpia, Philip O.
    Wynn, James L.
    Kelly-Scumpia, Kindra M.
    Strieter, Robert M.
    Moldawer, Lyle L.
    SHOCK, 2008, 29 : 79 - 79
  • [25] Effect of fibroblast growth factor 2 on stromal cell-derived factor 1 production by bone marrow stromal cells and hematopoiesis
    Nakayama, Takayuki
    Mutsuga, Noriko
    Tosato, Giovanna
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2007, 99 (03) : 223 - 235
  • [26] Stromal Cell-Derived Factor-1 Retention and Cardioprotection for Ischemic Myocardium
    Kanki, Sachiko
    Segers, Vincent F. M.
    Wu, Weitao
    Kakkar, Rahul
    Gannon, Joseph
    Sys, Stanislas U.
    Sandrasagra, Anthony
    Lee, Richard T.
    CIRCULATION-HEART FAILURE, 2011, 4 (04) : 509 - +
  • [27] Therapeutic Delivery of Stromal Cell-Derived Factor-1 for Injury Repair
    Yeboah, Agnes
    Yarmush, Martin L.
    Berthiaume, Francois
    NANO LIFE, 2016, 6 (01)
  • [28] Identification and expression of novel isoforms of human stromal cell-derived factor 1
    Yu, Lan
    Cecil, Jeffrey
    Peng, Sheng-Bin
    Schrementi, James
    Kovacevic, Steven
    Paul, Donald
    Su, Eric Wen
    Wang, Jian
    GENE, 2006, 374 : 174 - 179
  • [29] The biological sequelae of stromal cell-derived factor-1α in multiple myeloma
    Hideshima, T
    Chauhan, D
    Hayashi, T
    Podar, K
    Akiyama, M
    Gupta, D
    Richardson, P
    Munshi, N
    Anderson, KC
    MOLECULAR CANCER THERAPEUTICS, 2002, 1 (07) : 539 - 544
  • [30] Stromal cell-derived factor-1α is cardioprotective after myocardial infarction
    Saxena, Ankur
    Fish, Jason E.
    White, Michael D.
    Yu, Sangho
    Smyth, James W. P.
    Shaw, Robin M.
    DiMaio, J. Michael
    Srivastava, Deepak
    CIRCULATION, 2008, 117 (17) : 2224 - 2231